Central administration of a M1mAchR agonist alleviates the severity of Dextran sulfate sodium (DSS 5%)–induced colitis.

Vagotomy (VXP) or splenic neurectomy (NRX) were performed 10 days prior to initiating McN-A-343 (5 ng/kg/day, i.c.v.) treatment and/or colitis induction as described in Material and Methods. Macroscopic score, colon length, serum amyloid protein (SAP), colonic interferon-gamma (IFN-γ), interleukin (IL)-17, IL-12p70, IL-23 and IL-4. IL-12p70 and IL-23 release from splenic CD11c+ dendritic cells (DC). Splenic CD11c+ DCs were isolated from McN-A-343 (5 ng/kg/day, i.c.v. for 6 days)-treated groups of colitic mice subjected to sham-operation, vagotomy (VXP) or splenic neurectomy (NRX) on day 5 post-colitis induction. Effect of McN-A343 (in vivo) treatment on splenic CD11c+ DCs function and sequential CD4+ CD25−T cell activation. Splenic CD11c+ DCs isolated from different colitic group were cultured in for 24 h before being co-cultured with CD4+CD25−T cells isolated from naïve mice. The levels of IFN-γ and IL-17 and IL-4 were measured in media at 24 hrs.aPbPcPCentral administration of a M1mAchR agonist alleviates the severity of Dextran sulfate sodium (DSS 5%)–induced colitis.